Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

iCAD

This article was originally published in The Gray Sheet

Executive Summary

Company plans to file a 510(k) for the VeraLook computer-aided detection system for computed tomography (CT) colonography late this month or in April. iCAD previewed the investigational system at the European Society of Radiology annual meeting in Vienna March 6-10. The device can automatically identify polyps and streamline the image reading process, firm says. Data from a National Cancer Institute study published last fall supports using CT colonography, a non-invasive alternative to colonoscopy, as a screening option in cancers 10 mm or larger, but use of the technology may be limited by its cost (1"The Gray Sheet" Sept. 22, 2008, p. 21)

You may also be interested in...



CT Colonoscopy Gets Further Support From NCI Study In NEJM

Results of a major study sponsored by the National Cancer Institute and the American College of Radiology Imaging Network provide more support for computed tomographic colonography as an alternative to visual colonoscopy for colorectal cancer screening

EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions

It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.

How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies

UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel